AMRI has implemented several changes to further optimize its global business operations to enhance continuity from early development through to commercial supply and accelerate the company's global growth objectives.
Steven R. Hagen, PhD, senior vice president of manufacturing and pharmaceuticals, has assumed oversight of AMRI's global operations infrastructure ensuring that the manufacturing and development operations execute efficiently and safely and to AMRI's quality standards. The company says with this change, AMRI has improved line-of-sight of all global operations across all of its service offerings and all of its locations.
George Svokos, senior vice president, sales and general manager, API, has assumed responsibility for a newly created commercial function as chief commercial officer, which comprises sales and marketing, project management, and supply chain. In addition to leading the commercial function, Mr. Svokos will continue to spearhead AMRI's integrated API Manufacturing offering that includes chemical development and large-scale API manufacturing.
In tandem with the realignment, AMRI also announced the following senior management promotions. Milton Boyer was promoted to senior vice president of drug product manufacturing, from his former role as vice president of parenterals. Mr. Boyer's expertise from OsoBio will be applied across all phases of drug product, which spans from pre-formulation and formulation development all the way through to late-phase and commercial parenteral manufacturing.
Christopher Conway was promoted to senior vice president of global sales and marketing, and is responsible for all global sales, marketing, and customer operations functions. Mr. Conway, who joined AMRI in 2008, was most recently vice president of global sales and marketing. Before joining AMRI, Mr. Conway held sales and leadership positions of increasing responsibility at Johnson and Johnson.
To effectively support the growing interface between chemical development and API and best align AMRI's resources to effectively manage and transition customer projects, Rajesh Shenoy, PhD, was promoted to senior director of global chemical development. Dr. Shenoy has been with AMRI since 1998 in various roles of increasing responsibility. Most recently, Dr. Shenoy was senior director of global project panagement.
Separately, AMRI has named Jimmy Wang, PhD. to the newly created position of chief information officer. He replaces Carl Neumann, senior director, information technology, who retires this month. In this role, Dr. Wang will manage and oversee major technology initiatives at AMRI, as well as the day-to-day IT operations. Among his responsibilities will be to implement scalable and agile information technology solutions that align with AMRI's growth objectives and global operations.
Dr. Wang brings 25 years of experience managing and deploying technology innovations to various technology, telecommunications, and global pharmaceutical companies. Most recently he served as senior vice president and chief information officer at OPKO Health Inc., where he established the company's global IT governance process and transformed IT into a centralized delivery organization. Before OPKO Health, Dr. Wang was senior vice president and chief information officer at Vertex Pharmaceuticals Inc., where he played a major role in managing implementation, consolidation, and support of Enterprise Operations Support Systems, as well as led the area of scientific computing to use technology to support the area of Innovation and Research. Before Vertex, Dr. Wang was at Teva Pharmaceuticals-America, where he was vice president and chief information officer.